U.S. Auto Stock News

If you are wondering whether CME Group at around US$262 per share reflects fair value or an opportunity, this article breaks down what the current price might be implying about the stock. The stock is up 2.4% over the last week, even though it is down 8.2% over the past month, 2.8% year to date, and has returned 0.5% over the last year. Longer term returns of 63.6% over three years and 49.1% over five years provide additional context. Recent headlines around CME Group have continued to focus...

Ford Motor (NYSE:F) is ramping up F Series truck production after supply disruptions from major fires at primary aluminum supplier Novelis. Novelis has restarted its hot mill operations, restoring a key aluminum source for Ford's truck manufacturing. The earlier outages contributed to a significant shortfall in planned F Series output for 2025, which Ford now aims to recover. The production catch up plan is expected to influence revenues, dealer lot availability, and share in the full size...

This article examines whether General Dynamics at US$358.86 is priced for perfection or still offers value, focusing on what the current share price implies. The stock has returned 5.1% over the past week, 3.6% over the past month, 4.5% year to date and 30.6% over the past year, with longer term returns of 77.5% over three years and 112.8% over five years shaping how investors think about risk and reward. Recent news coverage has focused on General Dynamics' position as a major US defense...

Wondering if Electronic Arts at around US$203 per share still offers fair value, or if the recent run has pushed the stock too far. The stock is roughly flat over the past week, up 1.4% over the last month, slightly down 0.7% year to date, yet has delivered 35.9% over 1 year, 59.8% over 3 years and 46.9% over 5 years, which can change how you think about risk and return. Recent coverage has focused on Electronic Arts as a large US gaming company, including ongoing attention on its content...

Harrow (HROW) put vernal keratoconjunctivitis back in focus with the relaunch of VERKAZIA, a steroid sparing calcineurin inhibitor eye drop, backed by an access centric commercial push. See our latest analysis for Harrow. The VERKAZIA relaunch has come alongside a sharp improvement in recent share price momentum, with a 1 month share price return of 29.69% and a 3 month share price return of 10.41%. This is despite the year to date share price return being down 24.56% and the 5 year total...

NVR (NVR) shares came under pressure after the company reported quarterly revenue down 21.7% year on year, missing analysts' expectations by 7.8%. Adjusted operating income also fell short, and investors responded by selling. See our latest analysis for NVR. Despite the post earnings setback, NVR's recent 1 month share price return of 11.8% contrasts with a year to date share price decline of 11%. The 5 year total shareholder return of 37.9% points to steadier long term compounding and...

Wondering whether Ategrity Specialty Insurance Company Holdings at US$21.02 is pricing in its potential, or leaving room on the table for value focused investors. The stock has moved 8.1% over the past week and 8.4% over the past month, while being down 12.4% over the last year, which may have shifted how investors view both its upside and its risks. Recent headlines have focused on Ategrity Specialty Insurance Company Holdings as part of broader interest in specialty insurers, with...

LendingClub’s recent annual meeting approved another amendment to its Certificate of Incorporation, while Q1 2026 results showed higher earnings, stronger loan originations, and better credit performance alongside plans to expand into home improvement financing and rebrand as Happen Bank. This combination of operational momentum, tighter credit outcomes, and a shift toward broader consumer finance offerings marks a meaningful evolution in LendingClub’s business profile. We’ll now examine how...

Relay Therapeutics recently gained shareholder approval at its June 9, 2026 annual meeting to amend its certificate of incorporation and raise its authorized common stock capacity from 300,000,000 to 450,000,000 shares. At the same time, research firms highlighted encouraging initial clinical data for zovegalisib in vascular malformations, prompting more optimistic assessments of the drug’s commercial potential. We’ll now examine how the upgraded outlook for zovegalisib’s commercial...

Trane Technologies (NYSE:TT) has appointed Donald E. Simmons as Chief Operating Officer. Simmons has been with the company for 25 years and has held leadership roles across multiple business units. As COO, he will oversee all regional business units and operations with a focus on tighter operational alignment. The appointment is positioned as an important step in advancing the company’s growth strategy. Trane Technologies, traded on the NYSE under the ticker TT, focuses on heating,...

Tripadvisor (NasdaqGS:TRIP) has released its 2026 Travelers' Choice Best of the Best Hotels awards. The rankings highlight hotels in the US, Vietnam, Indonesia, and Ireland based on traveler reviews and experiences. The awards spotlight emerging travel trends and global hospitality quality across several key destinations. Tripadvisor, through its core reviews and travel guidance platform, plays a central role in how travelers research and select hotels worldwide. The 2026 Travelers' Choice...

Investors may wish to note that the Director of Silvaco Group, Inc. , Iliya Pesic, recently netted US$78k from selling...

Shoe Carnival, Inc.'s ( NASDAQ:SCVL ) recent soft profit numbers didn't appear to worry shareholders, as the stock...

Activist hedge fund Jana Partners has publicly urged Fiserv (NasdaqGS:FISV) to divest additional non core assets and overhaul its board of directors. The fund is pressing for new directors with payments and banking software expertise after holding private discussions with the company. Jana Partners has increased its stake in Fiserv, signaling a more assertive campaign to influence the company’s direction. Fiserv (NasdaqGS:FISV) operates in payments and financial technology, providing...

Viking Therapeutics (NasdaqCM:VKTX) has appointed Dr. Hubert C. Chen as chief medical officer. Dr. Chen brings extensive experience in drug discovery, clinical development, and regulatory strategy. The appointment expands the company’s senior leadership as its pipeline of metabolic and endocrine therapies progresses. Viking Therapeutics focuses on developing therapies for metabolic and endocrine disorders, areas that continue to attract attention as obesity, liver disease, and related...

Dana stock performance snapshot Dana (DAN) has drawn investor attention after recent trading, with the stock down 15% over the past day and 18% over the past week, extending a month decline of 11%. See our latest analysis for Dana. That sharp 15.1% one day share price decline adds to weaker recent momentum, even though year to date the share price return remains positive and the 1 year total shareholder return of 76.3% is much stronger. If recent volatility has you reassessing opportunities...

Earlier this week, nCino reported Q1 revenue of US$159.4 million, up 10.6% year on year and ahead of analyst expectations, alongside beats on billings and EBITDA. Management also emphasized growing customer validation of its AI product strategy and increased investment in the platform, underlining how AI is becoming central to nCino’s value proposition. Next, we’ll explore how this stronger-than-expected quarter and progress on AI integration may influence nCino’s broader investment...

In June 2026, Organon reported that the US FDA approved a supplemental Biologics License Application expanding TOFIDENCE, a tocilizumab biosimilar to ACTEMRA, to treat CAR T cell-induced severe cytokine release syndrome and certain hospitalized COVID-19 patients aged 2 years and older. This makes TOFIDENCE the first tocilizumab biosimilar available in the US across a broad range of autoimmune and acute inflammatory indications, potentially reinforcing Organon’s focus on expanding its...

Wondering if Goldman Sachs Group at US$1,035.64 is still offering value after a strong run, or if most of the opportunity is already priced in. The stock is down 5.2% over the past week, up 9.5% over the past month, up 13.3% year to date and up 69.0% over the past year. This naturally raises questions about both growth potential and changing risk perceptions. Recent coverage has focused on how a long stretch of strong returns, including a gain of very large magnitude over three years and...

Pagaya Technologies (NasdaqCM:PGY) is expanding its AI-powered underwriting partnership with Upgrade, Inc. into the Buy Now, Pay Later Flex Pay platform. The move extends Pagaya’s credit decisioning tools from personal loans into point of sale lending, with a focus on travel-related transactions. This development broadens Pagaya’s exposure to the BNPL asset class and introduces new use cases within Upgrade’s ecosystem. Pagaya Technologies runs an AI driven credit analysis and underwriting...

Skyworks Solutions recently showcased its latest power and gate driver technologies at PCIM Europe 2026, highlighting solutions for AI data centers, electric vehicles and industrial high‑power systems, including SelVCD™ and second‑generation ProVCD™ platforms. By tying its SelVCD™ and ProVCD™ gate‑drive innovations directly to AI server power flows and EV traction inverters, Skyworks underscored a push beyond mobile handsets into higher‑value power electronics markets. Now we’ll examine how...

If you are wondering whether Western Digital stock is still offering value after its huge run, this article walks through what the current price may be implying about the company. The stock closed at US$529.29, with returns that include a 7 day move that declined 8%, a 30 day gain of 8.3%, and a very large multi year return, which naturally raises questions about future upside and risk. Recent headlines have focused on Western Digital's role in data storage and its exposure to themes like...

If you are wondering whether Main Street Capital at around US$51.74 is attractively priced or asking too much for its prospects, you are asking the right question for this stock. The share price is down 0.5% over the past week, 2.2% over the past month, and 16.2% year to date, even though the 3 year and 5 year returns sit at 67.3% and 82.6% respectively. Recent attention on Main Street Capital has centered on how its business development model fits into a higher rate backdrop and what that...

In recent days, The Cheesecake Factory’s first-quarter 2026 results showed a 1.6% increase in same-store sales, and JPMorgan shifted its rating on the stock from Underweight to Neutral. This combination of improving same-store performance and a more constructive analyst stance has sharpened attention on the company’s profit margin outlook and overall business momentum. With profit margins now under a brighter spotlight following the strong quarter, we’ll explore how this development...